|Bid||5.08 x 1400|
|Ask||5.30 x 1100|
|Day's Range||5.06 - 5.36|
|52 Week Range||1.94 - 19.10|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 13, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
Shares of Edesa Biotech Inc (NASDAQ:EDSA) fell by 4.45% from the previous closing price. President *Brooks Michael J filed a Form 4 with the SEC on Thursday, March 25. The insider bought 4,500 shares at an average price of $5.08. After the transaction, the executive's stake in Edesa Biotech Inc. moved to 9,741 shares. The Importance of Insider Transactions While transactions from an insider shouldn't be used as the sole item to make an investment or trading decision, an insider buying or selling stock in their company can be a good added factor that leads to more conviction in a decision. Insiders buying stock after a notable sell off can indicate an insider's long-term belief in the success of the company; insiders buying stock at new highs can be an indication the exec doesn't feel the stock is overvalued. Conversely, insiders who are selling stock at new lows can potentially indicate some kind of capitulation moment. Insiders selling at new highs can indicate that exec wants to "take some profit" and "lock in a gain." Transaction Codes To Focus On Wall Street tends to focus on insider transactions which take place in the open market, viewed inside a Form 4 filing via codes P for purchase and S for sale. If the transaction was an open-market transaction, that means that the insider made a conscious decision for the company's stock moving forward. Transaction codes besides P or S aren't relatively important as they are seldom tied to a decision by the executive. For example, transaction code A is indicative of an insider being forced to sell shares to attain compensation. Moreover, transaction code C indicates the conversion of an option. See more from BenzingaClick here for options trades from BenzingaWhy Edesa Biotech Is Trading Higher Today12 Health Care Stocks Moving In Monday's Pre-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
TORONTO, ON / ACCESSWIRE / March 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has entered into a definitive license agreement under which the company, through a subsidiary, has acquired additional global rights to a non-steroidal anti-inflammatory technology that forms the basis of the company's EB01 and EB02 drug candidates.